Core Viewpoint - The article highlights the innovative development and market potential of Syntellix AG's bioabsorbable magnesium alloy implants, particularly the MAGNEZIX® series, which offer significant advantages over traditional metal implants in orthopedic surgeries [2][23]. Product Introduction - Syntellix AG's "bioabsorbable magnesium alloy compression screws" are made from magnesium-based alloy MgYREZr, designed to gradually degrade and be replaced by endogenous new tissue in the body [2][4]. - The MAGNEZIX® product line includes various types of screws and implants, such as MAGNEZIX® CS for small bone fractures and MAGNEZIX® CBS with enhanced antibacterial properties [4][9]. Key Features - The magnesium alloy's biomechanical properties closely resemble human bone, promoting bone growth and regeneration [8]. - The screws are designed to fully degrade within approximately 12 months, eliminating the need for removal surgeries and reducing the risk of secondary operations [9][11]. Clinical Research and Performance - MAGNEZIX® screws have been used in thousands of surgeries globally, demonstrating superior bone healing rates and patient satisfaction compared to traditional non-degradable metal implants [10][19]. - A study comparing MAGNEZIX® CS screws with titanium screws in Hallux valgus surgeries showed no significant difference in stability, bone healing, and patient satisfaction, with a 100% satisfaction rate reported [10][11]. Market Overview - The global orthopedic implant market is projected to grow from $47.38 billion in 2024 to $71.74 billion by 2032, with a compound annual growth rate of 5.3% [22]. - The demand for bioabsorbable implants is increasing due to their natural degradation properties and compatibility with bone tissue, positioning magnesium alloys as a new direction in the industry [22]. Company Background - Syntellix AG, founded in 2008 and headquartered in Hannover, Germany, specializes in the development and sale of bioabsorbable metal implants made from magnesium alloys [23]. - The company claims its implants can reduce surgical time, costs, pain, and infection risks by half compared to traditional titanium or steel implants [23].

思宇年度活动回顾： 首届全球眼科大会 | 首届全球骨科大会 | 首届全球心血管大会 | 首届全球医美科技大会 即将召开： 2025年7月17日，第二届全球医疗科技大会 2025年9月3-5日，第三届全球手术机器人大会 公司介绍 中欧智薇（上海）机器人有限公司是华科润旗下子公司， 专注于数字化骨科产品和微型手术机器人技术。 2021年底，华科润与欧洲创新手术机器人公司 Interventional Systems（简称 INS）在上海合作成立中欧智薇（上海）机器人有限公司，向市场推出 具有显著差异 化及创新性的新一代微型骨科手术机器人 。 ▲图片源 自公司官方公众号 2025年6月27日，国家药品监督管理局批准了 中欧智薇（上海）机器人有限公司 的 "脊柱外科手术导航定位设备" （国械注准20253011259）， 深圳迈微医疗 科技有限公司 的" 心脏脉冲电场消融设备 "（国械注准20253011258）和 德国新特利斯股份公司 的" 生物可吸收镁合金加压螺钉 "（国械注进20253130280） 三个创新产品注册申请 。 截至目前，我国上市的创新医疗器械累计 360 项。 | 358 | 脊柱外科手术导航定 ...